IMV (NASDAQ:IMV – Get Rating) will be issuing its quarterly earnings data before the market opens on Friday, May 13th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.
IMV (NASDAQ:IMV – Get Rating) last released its quarterly earnings results on Thursday, March 17th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $0.04 million during the quarter. IMV had a negative net margin of 19,535.29% and a negative return on equity of 145.26%. During the same period in the prior year, the firm earned ($0.11) earnings per share. On average, analysts expect IMV to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ IMV opened at $1.08 on Friday. The firm has a market capitalization of $88.80 million, a P/E ratio of -2.25 and a beta of 1.33. The business has a fifty day simple moving average of $1.31 and a 200 day simple moving average of $1.35. IMV has a 12 month low of $1.05 and a 12 month high of $2.87. The company has a current ratio of 5.01, a quick ratio of 5.01 and a debt-to-equity ratio of 0.90.
A number of large investors have recently made changes to their positions in IMV. Virtu Financial LLC bought a new position in shares of IMV during the 4th quarter worth $77,000. Susquehanna International Group LLP grew its stake in shares of IMV by 50.6% during the 4th quarter. Susquehanna International Group LLP now owns 205,492 shares of the company’s stock worth $251,000 after acquiring an additional 69,029 shares during the period. CIBC World Markets Inc. grew its stake in shares of IMV by 101.6% during the 4th quarter. CIBC World Markets Inc. now owns 24,486 shares of the company’s stock worth $30,000 after acquiring an additional 12,338 shares during the period. Geode Capital Management LLC grew its stake in shares of IMV by 44.7% during the 3rd quarter. Geode Capital Management LLC now owns 38,325 shares of the company’s stock worth $63,000 after acquiring an additional 11,833 shares during the period. Finally, Morgan Stanley grew its stake in shares of IMV by 13,722.0% during the 2nd quarter. Morgan Stanley now owns 41,466 shares of the company’s stock worth $91,000 after acquiring an additional 41,166 shares during the period. Hedge funds and other institutional investors own 13.03% of the company’s stock.
IMV Company Profile (Get Rating)
IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer.
- Get a free copy of the StockNews.com research report on IMV (IMV)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.